131 related articles for article (PubMed ID: 10491420)
1. Photoimmunotherapy and ovarian cancer: an improbable fiction or a palpable hit?
Tochner ZA; Hahn S; Glatstein E
J Natl Cancer Inst; 1999 Sep; 91(18):1526-7. PubMed ID: 10491420
[No Abstract] [Full Text] [Related]
2. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo.
Duska LR; Hamblin MR; Miller JL; Hasan T
J Natl Cancer Inst; 1999 Sep; 91(18):1557-63. PubMed ID: 10491432
[TBL] [Abstract][Full Text] [Related]
3. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model.
Goff BA; Hermanto U; Rumbaugh J; Blake J; Bamberg M; Hasan T
Br J Cancer; 1994 Sep; 70(3):474-80. PubMed ID: 8080733
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria-targeted polyprodrug nanoparticles induce mitochondrial stress for immunogenic chemo-photodynamic therapy of ovarian cancer.
Zhang W; Chen G; Chen Z; Yang X; Zhang B; Wang S; Li Z; Yang Y; Wu Y; Liu Z; Yu Z
J Control Release; 2024 Jul; 371():470-483. PubMed ID: 38849094
[TBL] [Abstract][Full Text] [Related]
5. C225 and PDT combination therapy for ovarian cancer: the play's the thing.
Cengel KA; Hahn SM; Glatstein E
J Natl Cancer Inst; 2005 Oct; 97(20):1488-9. PubMed ID: 16234556
[No Abstract] [Full Text] [Related]
6. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
del Carmen MG; Rizvi I; Chang Y; Moor AC; Oliva E; Sherwood M; Pogue B; Hasan T
J Natl Cancer Inst; 2005 Oct; 97(20):1516-24. PubMed ID: 16234565
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
Berek JS
Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
[TBL] [Abstract][Full Text] [Related]
8. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates.
Molpus KL; Hamblin MR; Rizvi I; Hasan T
Gynecol Oncol; 2000 Mar; 76(3):397-404. PubMed ID: 10684717
[TBL] [Abstract][Full Text] [Related]
10. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study.
Muller M; Chérel M; Dupré PF; Gouard S; Collet M; Classe JM
Eur Surg Res; 2011; 46(3):139-47. PubMed ID: 21372578
[TBL] [Abstract][Full Text] [Related]
12. Antitumor antibodies for immunotherapy of ovarian carcinomas.
Wagner U
Hybridoma; 1993 Oct; 12(5):521-8. PubMed ID: 8300125
[No Abstract] [Full Text] [Related]
13. Ovarian carcinoma therapy with monoclonal antibodies.
Canevari S; Miotti S; Bottero F; Valota O; Colnaghi MI
Hybridoma; 1993 Oct; 12(5):501-7. PubMed ID: 8300122
[No Abstract] [Full Text] [Related]
14. High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer.
Kotz KW; Schilder RJ
Semin Oncol; 1995 Jun; 22(3):250-62. PubMed ID: 7777869
[No Abstract] [Full Text] [Related]
15. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
[TBL] [Abstract][Full Text] [Related]
17. Recent immunologic advances affecting the management of ovarian cancer.
Freedman RS
Clin Obstet Gynecol; 1985 Dec; 28(4):853-71. PubMed ID: 4075635
[No Abstract] [Full Text] [Related]
18. Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy.
Sato K; Watanabe R; Hanaoka H; Nakajima T; Choyke PL; Kobayashi H
Oncotarget; 2016 Mar; 7(12):14324-35. PubMed ID: 26885688
[TBL] [Abstract][Full Text] [Related]
19. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Grisham RN; Berek J; Pfisterer J; Sabbatini P
Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
[TBL] [Abstract][Full Text] [Related]
20. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
